Introduction/Background To investigate CA-125 levels in uterine papillary serous carcinoma (UPSC) patients.

Methodology From January 2015 to December 2018, we collected data of UPSC and preoperative CA-125 levels of patients. Subsequent parameters were evaluated; age, preoperative endometrial sampling results, tumor size, lymph node involvement, LVSI, depth of myometrial invasion, stage.

Results For the final analysis, 25 patients were eligible. Mean and %95 confidence interval for CA-125 levels in UPSC patients was 130.56 IU/ml (%95 CI: 5.18–255.93). Minimum was 4 and maximum was 1454 IU/ml (median=19). Mean age was 63.04 + 8.7. In lymph node positive patients mean CA-125 was 114.8 IU/ml and lymph node negative patients 134.5 IU/ml (p=0,9). In patients with LVSI mean CA-125 level was 170.73 IU/ml and patients that didn't present with LVSI 76.77 IU/ml (p=0.77). There was no relationship between the tumor size and CA-125 level (Pearson coefficient 0.069, p=0,745). In patients with more than %50 myometrial invasion, mean CA-125 level was 137.66 IU/ml and was less than 50% 126.56 IU/ml (p=0.932). Mean CA-125 level for tumors that were spread beyond the uterus were 257.08 IU/ml and for the tumors that were confined to the uterus were 13.76 IU/ml (p=0,043).

Conclusion Our results suggest that, preoperative CA-125 levels is a good predictor for extrauterine involvement and for advanced stage. There was no correlation between CA-125 and LVSI, lymph node positivity, myometrial invasion, age.

Disclosure Nothing to disclose.